170 related articles for article (PubMed ID: 28744104)
1. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort.
Bernuth S; Grimm D; Vollmar J; Darstein F; Mittler J; Heise M; Hoppe-Lotichius M; Galle PR; Lang H; Zimmermann T
Drug Des Devel Ther; 2017; 11():2131-2138. PubMed ID: 28744104
[TBL] [Abstract][Full Text] [Related]
2. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
[TBL] [Abstract][Full Text] [Related]
3. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
5. Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study.
Jiménez-Romero C; Justo I; Marcacuzco A; García V; Manrique A; García-Sesma Á; Calvo J; Fernández I; Martín-Arriscado C; Caso Ó
Int J Surg; 2021 Jul; 91():105981. PubMed ID: 34098075
[TBL] [Abstract][Full Text] [Related]
6. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort.
Kauffman-Ortega E; Ruiz-Manriquez J; Olivas-Martinez A; Campos-Murguía A; Flores-García NC; Márquez-Guillén E; López-Yáñez S; Sánchez-Ávila F; Toapanta-Yanchapaxi L; Paez-Zayas VM; García-Juárez I
Arch Med Res; 2021 Oct; 52(7):713-718. PubMed ID: 33966917
[TBL] [Abstract][Full Text] [Related]
7. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
8. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
9. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Takaguchi K; Toyoda H; Tsutsui A; Suzuki Y; Nakamuta M; Imamura M; Senoh T; Nagano T; Tada T; Tachi Y; Hiraoka A; Michitaka K; Shibata H; Joko K; Okubo H; Tsuji K; Takaki S; Watanabe T; Ogawa C; Chayama K; Kumada T; Kudo M; Kumada H
J Gastroenterol; 2019 Aug; 54(8):742-751. PubMed ID: 30848363
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
Ji F; Wei B; Yeo YH; Ogawa E; Zou B; Stave CD; Li Z; Dang S; Furusyo N; Cheung RC; Nguyen MH
Aliment Pharmacol Ther; 2018 Mar; 47(5):550-562. PubMed ID: 29327780
[TBL] [Abstract][Full Text] [Related]
11. Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance.
Roche B; Coilly A; Roque-Afonso AM; Samuel D
Viruses; 2015 Sep; 7(9):5155-68. PubMed ID: 26404355
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation.
Ponziani FR; Annicchiarico EB; Siciliano M; D'Aversa F; Pompili M; Gasbarrini A
World J Gastroenterol; 2013 Jun; 19(21):3255-62. PubMed ID: 23745027
[TBL] [Abstract][Full Text] [Related]
13. Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.
Jung J; Kwon JH; Song GW; Tak EY; Kirchner VA; Lee SG
J Gastrointest Surg; 2018 Aug; 22(8):1334-1342. PubMed ID: 29679347
[TBL] [Abstract][Full Text] [Related]
14. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
[TBL] [Abstract][Full Text] [Related]
16. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
17. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
El-Hamamsy M; Montasser IF; Mansy AE; Nabet DE; El-Meteini M
J Clin Pharm Ther; 2019 Jun; 44(3):447-453. PubMed ID: 30714175
[TBL] [Abstract][Full Text] [Related]
18. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
Werner CR; Schwarz JM; Egetemeyr DP; Beck R; Malek NP; Lauer UM; Berg CP
World J Gastroenterol; 2016 Sep; 22(35):8050-9. PubMed ID: 27672299
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
Beig J; Orr D; Harrison B; Gane E
Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis.
Liu J; Ma B; Cao W; Li M; Bramer WM; Peppelenbosch MP; Pan Q
Transpl Infect Dis; 2019 Apr; 21(2):e13047. PubMed ID: 30615227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
